Market capitalization | $683.23m |
Enterprise Value | $993.51m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | negative |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-173.36m |
Free Cash Flow (TTM) Free Cash Flow | $-154.91m |
Cash position | $123.16m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
3 Analysts have issued a Omeros Corporation forecast:
3 Analysts have issued a Omeros Corporation forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.85 -0.85 |
0%
0%
|
|
EBITDA | -173 -173 |
5%
5%
|
EBIT (Operating Income) EBIT | -173 -173 |
5%
5%
|
Net Profit | -135 -135 |
773%
773%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.
Head office | United States |
CEO | Gregory Demopulos |
Employees | 198 |
Founded | 1994 |
Website | www.omeros.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.